Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine

Suckow, Mark A.; Rosen, Elliot D.; Wolter, William R.; Sailes, Valerie; Jeffrey, Randy; Tenniswood, Martin

doi:10.1007/s00262-006-0278-8

Cited by 16 publications

(10 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may explain a previous report by Suckow, et al . that showed that prostate tissue vaccine stimulated a Th1 response and specifically prevented prostate cancer growth [19], [44]. In a future study, it will be of interest to assess the effects of SIS, with or without non-self antigens, on expressions of co-stimulatory molecules by antigen-presenting cells.…”

Section: Discussionmentioning

confidence: 99%

Extracellular Matrix from Porcine Small Intestinal Submucosa (SIS) as Immune Adjuvants

Aachoui

Ghosh

2011

PLoS ONE

View full text Add to dashboard Cite

Porcine small intestinal submucosa (SIS) of Cook Biotech is licensed and widely used for tissue remodeling in humans. SIS was shown to be highly effective as an adjuvant in model studies with prostate and ovarian cancer vaccines. However, SIS adjuvanticity relative to alum, another important human-licensed adjuvant, has not yet been delineated in terms of activation of innate immunity via inflammasomes and boosting of antibody responses to soluble proteins and hapten-protein conjugates. We used ovalbumin, and a hapten-protein conjugate, phthalate-keyhole limpet hemocyanin. The evaluation of SIS was conducted in BALB/c and C57BL/6 mice using both intraperitoneal and subcutaneous routes. Inflammatory responses were studied by microarray profiling of chemokines and cytokines and by qPCR of inflammasomes-related genes. Results showed that SIS affected cytokine and chemokines microenvironments such as up-regulation of IL-4 and CD30-ligand and activation of chemotactic factors LIX and KC (neutrophil chemotactic factors), MCP-1 (monocytes chemotactic factors), MIP 1-α (macrophage chemotactic factor) and lymphotactin, as well as, growth factors like M-CSF. SIS also promoted gene expression of Nod-like receptors (NLR) and associated downstream effectors. However, in contrast to alum, SIS had no effects on pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) or NLRP3, but it appeared to promote both Th1 and Th2 responses under different conditions. Lastly, it was as effective as alum in engendering a lasting and specific antibody response, primarily of IgG1 type.

show abstract

Section: Discussionmentioning

confidence: 99%

Extracellular Matrix from Porcine Small Intestinal Submucosa (SIS) as Immune Adjuvants

Aachoui

Ghosh

2011

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Further, tumor material harvested from other sources could be used for preparation of vaccines. For example, our laboratory has previously shown that a xenogeneic tissue vaccine composed of harvested subcutaneous PAIII prostate tumors in LW rats stimulated sufficient immunity in immunocompetent Ncr-Foxn1 \nu[ mice such that, when their splenocytes were incubated with human PC346C prostate cancer cells and administered to syngeneic nu/nu mice, nearly 70% of the immunodeficient mice were completely free of tumor growth compared to none of the controls [17]. It appeared that this protective response was mediated by Th1 immunity.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of prostate cancer metastasis by administration of a tissue vaccine

Suckow

Wolter

Sailes

2008

Clin Exp Metastasis

Self Cite

View full text Add to dashboard Cite

Immunotherapy by vaccination represents a novel method for treatment of cancer. In this regard, vaccines with the broadest possible menu of relevant antigens stand the greatest chance of success. Tissue vaccines are composed of material harvested directly from tumors and contain not only antigens associated with neoplastic epithelium, but also those that may be unique to in vivo growth and antigens associated with the tumor stroma. To test the hypothesis that a tissue vaccine, produced by glutaraldehyde fixation of harvested syngeneic prostate tumors (GFT vaccine), could be used for treatment of prostate cancer, male Lobund-Wistar (LW) rats were treated with methylnitrosourea (MNU) and testosterone propionate to induce autochthonous prostate tumors. Tumor-bearing rats were randomly assigned to one of three treatment groups: no treatment (11 rats); vaccination with media (10 rats); or vaccination with the GFT vaccine (19 rats). Vaccination was given initially with Freund's complete adjuvant and booster doses were given with incomplete Freund's adjuvant every week until the time of euthanasia. There were no significant differences in mean tumor weight between groups; however, GFT-vaccinated rats had a prolonged survival time; and 4/19 (21%) GFT-vaccinated rats were found to be tumor-free compared to none of the untreated or media-treated controls. Further, pulmonary metastasis occurred in only 5/15 (33%) of GFT-vaccinated rats compared to 10/11 (91%) and 10/10 (100%) of untreated and media-vaccinated controls, respectively. Supernatants of cultured splenocytes from similarly media- and GFT-vaccinated rats demonstrated significant (P < 0.001) increases in IFN-gamma and TNF-alpha from splenocytes of GFT-vaccinated rats, suggesting that GFT vaccination stimulates a Th1 response. In summary, treatment of tumor-bearing rats with a tissue vaccine stimulated a protective immune response that resulted in complete tumor regression in 21% of animals and reduced the number of animals with any evidence of metastasis by nearly 70%. These results suggest that tissue vaccines may be useful for the treatment of prostate cancer.

show abstract

“…185 Another approach using a xenogeneic tissue vaccine has recently been shown to stimulate protective immunity against human PC cells. 186 …”

Section: Whole-tumour Cell Vaccinesmentioning

confidence: 99%

Immunology and immunotherapy approaches for prostate cancer

Elkord

2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Several mechanisms that impair the immune response to promote tumour progression are reported. These mechanisms aim to reduce the ability of antigen-presenting cells to present antigen and activate naïve T cells to support an active immune response or to create a suppressive environment that induce non-functional tumour-associated antigen-specific T cells. Prostate cancer (PC) alone accounts for 33% of incident cancer cases and about 9% of all cancer-related deaths among men in the USA during 2006. Whereas androgen deprivation has remained the first line of therapy for advanced PC, other therapies are still required due to progression to an androgen-resistant state and eventually loss of control in patients receiving hormonal therapy. Immunotherapy seems to be a promising approach to enhance tumour-specific T-cell responses in different cancers including prostate. More importantly, clinical trials in advanced PC patients have shown that immunotherapy may generate significant clinical responses. Immunology and immunotherapy aspects of PC with focus on prostate-specific antigen will be presented.

show abstract

Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine

Cited by 16 publications

References 46 publications

Extracellular Matrix from Porcine Small Intestinal Submucosa (SIS) as Immune Adjuvants

Extracellular Matrix from Porcine Small Intestinal Submucosa (SIS) as Immune Adjuvants

Inhibition of prostate cancer metastasis by administration of a tissue vaccine

Immunology and immunotherapy approaches for prostate cancer

Contact Info

Product

Resources

About